414 related articles for article (PubMed ID: 25257732)
1. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
Debes A; Bauer M; Kremer S
Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
[TBL] [Abstract][Full Text] [Related]
3. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.
Aghamohammadi A; Farhoudi A; Nikzad M; Moin M; Pourpak Z; Rezaei N; Gharagozlou M; Movahedi M; Atarod L; Afshar AA; Bazargan N; Hosseinpoor AR
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):60-4. PubMed ID: 14756466
[TBL] [Abstract][Full Text] [Related]
4. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases.
Dashti-Khavidaki S; Aghamohammadi A; Farshadi F; Movahedi M; Parvaneh N; Pouladi N; Moazzami K; Cheraghi T; Mahdaviani SA; Saghafi S; Heydari G; Abdollahzade S; Rezaei N
J Investig Allergol Clin Immunol; 2009; 19(2):139-45. PubMed ID: 19476018
[TBL] [Abstract][Full Text] [Related]
5. Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study.
Blažek B; Misbah SA; Soler-Palacin P; McCoy B; Leibl H; Engl W; Empson V; Gelmont D; Nikolov N
Immunotherapy; 2015; 7(7):753-63. PubMed ID: 25865232
[TBL] [Abstract][Full Text] [Related]
6. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
Lozano-Blasco J; Martín-Mateos MA; Alsina L; Domínguez O; Giner MT; Piquer M; Alvaro M; Plaza AM
Allergol Immunopathol (Madr); 2014; 42(2):136-41. PubMed ID: 23253680
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
[TBL] [Abstract][Full Text] [Related]
8. Immediate adverse reactions to intravenous immunoglobulin in primary immune deficiencies: a single center experience.
Nain E; Kıykım A; Kasap NA; Barış S; Özen A; Aydıner EK
Turk J Pediatr; 2020; 62(3):379-386. PubMed ID: 32558411
[TBL] [Abstract][Full Text] [Related]
9. A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID).
Viallard JF; Brion JP; Malphettes M; Durieu I; Gardembas M; Schleinitz N; Hoarau C; Lazaro E; Puget S
Rev Med Interne; 2017 Sep; 38(9):578-584. PubMed ID: 28683953
[TBL] [Abstract][Full Text] [Related]
10. Adverse reactions of intravenous immunoglobulin.
Al-Wahadneh AM; Khriesat IA; Kuda EH
Saudi Med J; 2000 Oct; 21(10):953-6. PubMed ID: 11369961
[TBL] [Abstract][Full Text] [Related]
11. Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin.
Esmaeilzadeh H; Askarisarvestani A; Hosseini N; Samimi S; Shafiei A; Mahdaviani SA; Eslami N; Chavoshzadeh Z; Fallahi M; Khakbazanfard N; Shabestari MS; Aleyasin S; Nabavizadeh SH; Cheraghi T; Kalantari A; Ahmadiafshar A; Safari M; Eslamian MH; Molatefi R; Shirkani A; Heidarzadeh Arani M; Tavakol M; Bemanian MH; Arshi S; Nabavi M; Shokri S; Shahhosseini B; Mortazavi N; Nakhaei P; Nazari F; Fallahpour M; Ahanchian H; Moazzen N; Khoshkhui M; Motlagh AV; Aghamohammadi A; Abolhassani H; Yazdani R; Rezaei N
Clin Immunol; 2021 Sep; 230():108826. PubMed ID: 34418548
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
[TBL] [Abstract][Full Text] [Related]
13. Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states.
Tcheurekdjian H; Martin J; Kobayashi R; Wasserman R; Hostoffer R
Allergy Asthma Proc; 2006; 27(6):532-6. PubMed ID: 17176791
[TBL] [Abstract][Full Text] [Related]
14. Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience.
Kaba S; Keskindemirci G; Aydogmus C; Siraneci R; Erol Cipe F
Eur Ann Allergy Clin Immunol; 2017 Jan; 49(1):11-14. PubMed ID: 28120600
[TBL] [Abstract][Full Text] [Related]
15. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases.
Ochs HD; Pinciaro PJ;
J Clin Immunol; 2004 May; 24(3):309-14. PubMed ID: 15114062
[TBL] [Abstract][Full Text] [Related]
16. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
Günther G; Dreger B
Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
[TBL] [Abstract][Full Text] [Related]
17. A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency.
Krivan G; Chernyshova L; Kostyuchenko L; Lange A; Nyul Z; Derfalvi B; Musial J; Bellon A; Kappler M; Sadoun A; Bernatowska E
J Clin Immunol; 2017 Aug; 37(6):539-547. PubMed ID: 28711959
[TBL] [Abstract][Full Text] [Related]
18. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
[TBL] [Abstract][Full Text] [Related]
19. Safety monitoring of the intravenous immunoglobulin preparation Intratect® in primary and secondary immunodeficiencies: a prospective non-interventional study.
Bauhofer A; Dietrich RL; Schmeidl R
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):21-31. PubMed ID: 25345431
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]